Catalyst

Slingshot members are tracking this event:

Mast's EPIC Phase 3 Data for Vepoloxamer in Patients with Sickle Cell Disease Expected Mid Year

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
MSTX

100%

Additional Information

Additional Relevant Details "Announcing top-line data from the EPIC study continues to be our top priority."
http://ir.novavax.co...
Clinical Data MSTX announced via SEC filing they are expecting to lock their previously delayed Phase 3 EPIC data for sickle cell disease in July. They expect to release top-line data shortly afterwards. 
http://masttherapeut...
Management Comment CEO Brian Culley commented on July 25, 2016 in a note to shareholders, " We expect to report top-line data during September, so we appreciate that our lender has extended to October 14th the deadline for us to demonstrate positive results in our EPIC study or to prepay $10 million of the principal balance of the loan. If we have positive results on or before that date, the debt will remain in place and further principal payments will be deferred until March 1, 2017.  Here is a link to our filing with further description of the loan agreement amendment and a copy of the amendment itself.
http://masttherapeut...
Additional Relevant Details Top-line data from EPIC is forthcoming
http://masttherapeut...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 20, 2016
Occurred Source:
Related Keywords Sickle Cell Disease, Vepoloxamer, Phase 3 Epic Trial